Praxis Investment Management Inc. Decreases Holdings in Insulet Corporation $PODD

Praxis Investment Management Inc. decreased its position in shares of Insulet Corporation (NASDAQ:PODD) by 21.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,660 shares of the medical instruments supplier’s stock after selling 460 shares during the period. Praxis Investment Management Inc.’s holdings in Insulet were worth $522,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PODD. American Century Companies Inc. lifted its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Nuveen LLC acquired a new position in Insulet during the 1st quarter valued at approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC increased its stake in Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after purchasing an additional 179,850 shares in the last quarter. Vanguard Group Inc. increased its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its stake in Insulet by 89.1% during the 2nd quarter. Allianz Asset Management GmbH now owns 262,878 shares of the medical instruments supplier’s stock valued at $82,591,000 after purchasing an additional 123,862 shares in the last quarter.

Insiders Place Their Bets

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PODD. Piper Sandler upped their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Barclays upped their price target on shares of Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. The Goldman Sachs Group cut their price target on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Finally, Citigroup reiterated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $348.05.

Insulet Stock Up 0.7%

NASDAQ:PODD opened at $318.59 on Friday. The company’s fifty day moving average price is $326.22 and its 200-day moving average price is $302.21. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The firm has a market capitalization of $22.43 billion, a P/E ratio of 96.84, a PEG ratio of 2.66 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.